Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
The main aim of this trial is to determine whether there are fewer cardiovascular events when
patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of
optimal standard treatment after treatment with PCI, compared with placebo in combination
with optimal standard treatment. More specifically, we aim to investigate the benefits of a
daily low dose of colchicine in patients with coronary artery disease after treatment with
PCI, to confirm that a daily low dose of colchicine helps prevent additional incidents in
coronary artery disease, and to identify a subgroup of patients with CAD who are at increased
risk for cardiovascular events and could benefit most from colchicine.
Phase:
Phase 3
Details
Lead Sponsor:
AZ Sint-Jan AV
Collaborators:
Belgium Health Care Knowledge Centre University Hospital, Ghent